Abstracts tagged "osteoporosis"

Abstract Number: 1181 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Incident Fractures in Patients with Systemic Lupus Erythematosus on Dialysis
Brian Le^1,2, Jennifer Waller³, Reshmitha Radhakrishnan⁴, Sun Jung Oh⁴, Monique Bethel^2,5, Christopher Rice⁴ and Laura Carbone^2,6, ¹Department of Internal Medicine, Augusta University, Augusta, GA, ²Specialty Care, Charlie Norwood VA Medical Center, Augusta, GA, ³Biostatistics, Augusta University, Augusta, GA, ⁴School of Medicine, Augusta University, Augusta, GA, ⁵1120 15th Street, BI 5070, Augusta University, Augusta, GA, ⁶Rheumatology, Augusta University, Augusta, GA
Background/Purpose: Osteoporosis and osteoporotic fractures are significant comorbidities in patients with systemic lupus erythematosus (SLE). Hip fractures are being increasingly recognized as a complication of…
Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group , ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…
Abstract Number: 830 • 2015 ACR/ARHP Annual Meeting
Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis
Antonia Valenzuela¹, Murray Baron², Ariane L. Herrick³, Susana Proudman⁴, Wendy Stevens⁵, Tatiana Sofia Rodriguez-Reyna⁶, Alessandra Vacca⁷, Thomas A. Medsger Jr.⁸, Monique Hinchcliff⁹, Vivien Hsu¹⁰, David Fiorentino¹¹, Lorinda Chung¹² and the Canadian Scleroderma Research Group, and the ASIG rubric, ¹Stanford University School of Medicine, Stanford, CA, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁵Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷University Hospital of Cagliari, Rheumatology Unit, Monserrato, Italy, ⁸Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology, Northwestern University, Chicago, IL, ¹⁰Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ¹¹Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ¹²Stanford University, Palo Alto, CA
Background/Purpose: Calcinosis is a debilitating complication of systemic sclerosis (SSc). We sought to determine the clinical factors associated with calcinosis in an international multi-center collaborative…
Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Denise Boudreau¹, Onchee Yu¹, Akhila Balasubramanian², Jane Grafton¹, Heidi Wirtz³, Andreas Grauer³, D. Barry Crittenden³ and Delia Scholes¹, ¹Group Health Research Institute, Seattle, WA, ²Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…
Abstract Number: 2509 • 2015 ACR/ARHP Annual Meeting
Glucocorticoid Induced Osteoporosis Screening and Treatment: A Gender Comparison in a Cohort of Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting
Hajra Shah¹, Narender Annapureddy² and Ruchi Jain¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN
Background/Purpose: One-fourth of hip fractures occur in men. Men treated with oral glucocorticoids for at least 3 months are particularly at risk. Studies have suggested…
Abstract Number: 352 • 2015 ACR/ARHP Annual Meeting
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Eirik Ikdahl^1,2, Hege Kilander Høiberg³, Silvia Rollefstad², Andreas P Diamantopoulos^4,5, Grunde Wibetoe², Arthur Kavanaugh⁶, Inge C Olsen⁷, Tore K. Kvien⁷, Anne Grete Semb⁸ and Glenn Haugeberg⁹, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁴Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ⁵Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁶University of California San Diego, La Jolla, CA, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: There is an evidence vacuum concerning the mechanisms underlying the high atherosclerotic cardiovascular disease (ASCVD) burden in patients with psoriatic arthritis (PsA). In the…
Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 380 • 2015 ACR/ARHP Annual Meeting
Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
Sheena Ogando¹, Calie Santana², Irene Blanco³ and Barbara Mendez¹, ¹Rheumatology, Montefiore Medical Center, Bronx, NY, ²Medicine, Montefiore Medical Center, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucocorticoids are effective at treating rheumatologic diseases but are known to increase fracture risk. In 2010, the ACR developed recommendations for the prevention…
Abstract Number: 2314 • 2014 ACR/ARHP Annual Meeting
Dexa Testing in Long-Term Steroid Use
Beth Scholz, Internal medicine, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Risk stratification in the ACR glucocorticoid-induced osteoporosis guidelines includes DEXA testing, which is not universally implemented at our rheumatology clinic. DEXA utilization should be…
Abstract Number: 2315 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting
Hajra Shah, Narender Annapureddy, Joel A. Block and Ruchi Jain, Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: One-fourth of hip fractures occur in men. Three groups of men are at high risk for fracture: those who have already suffered a fragility…
Abstract Number: 2259 • 2014 ACR/ARHP Annual Meeting
Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis
Makoto Kaburaki, Kaichi Kaneko, Kotaro Shikano, Mai Kawazoe, Emiko Shindo, Hiroshi Sato, Natsuki Fujio, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Natsuko Kusunoki, Tomoko Hasunuma, Shinichi Kawai and Shotaro Masuoka, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose ,Osteoporosis is one of the serious complications of systemic glucocorticoid therapy. Reduced bone formation is the key process in patients with glucocorticoid-induced osteoporosis (GIOP),…
Abstract Number: 1835 • 2014 ACR/ARHP Annual Meeting
Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Robert A. Overman¹ and Chad L. Deal², ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Current National Osteoporosis Guidelines recommend treatment with an approved osteoporosis medication after hip and vertebral fracture. Only 20% of patients receive osteoporosis therapy after…
Abstract Number: 1246 • 2014 ACR/ARHP Annual Meeting
Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population
McCall Walker¹, Harmanjot K. Grewal², Adam Janot³, Mary Yu⁴, Sophia Cenac⁵, Matthew R. Lammi^6,7 and Lesley Ann Saketkoo⁸, ¹LSUHSC School of Medicine, New Orleans, LA, ²Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ³Department of Ophthalmology, Virginia Commonwealth University –Medical College of Virginia, Charlottesville, VA, ⁴Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ⁶Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁷Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁸Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis often involves pathological dysregulation of dependent factors of bone metabolism, e.g. calcitriol /calcium, and administration of high dose glucocorticoids (GCs) leading to low…
Abstract Number: 919 • 2014 ACR/ARHP Annual Meeting
Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65
Akhila Balasubramanian¹, Sally Wade², Robert A Adler³, Celia Fang (Lin)⁴, Michael Maricic⁵, Cynthia O'Malley¹, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Wade Outcomes Research and Consulting, Salt Lake City, UT, ³Internal Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, VA, ⁴Amgen, Thousand Oaks, CA, ⁵Catalina Pointe Rheumatology, Tucson, AZ, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Systemic glucocorticoid use can increase fracture risk, although dose-specific effects are not well understood, especially in younger adults. Underlying diseases (e.g., rheumatoid arthritis [RA])…
Abstract Number: 916 • 2014 ACR/ARHP Annual Meeting
Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density
MR McClung¹, A Chines², JP Brown³, A Diez-Perez⁴, H Resch⁵, J Caminis⁶, MA Bolognese⁷, S Goemaere⁸, HG Bone⁹, JR Zanchetta¹⁰, J Maddox², O Rosen², S Bray¹¹ and A Grauer², ¹Oregon Osteoporosis Center, Portland, OR, ²Amgen Inc., Thousand Oaks, CA, ³Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, ⁴Autonomous University of Spain, Barcelona, Spain, ⁵St. Vincent Hospital, Vienna, Austria, ⁶UCB, Raleigh, NC, ⁷Bethesda Health Research Center, Bethesda, MD, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Michigan Bone and Mineral Clinic, Detroit, MI, ¹⁰Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹¹Amgen Ltd., Cambridge, United Kingdom
Background/Purpose: We previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].